Go Back

Major League Lacrosse Partners with Biodesix

BOSTON & BOULDER, CO, July 13, 2019 - Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.

“The health and safety of our players, coaches, and staff is the number one priority for the 2020 Major League Lacrosse Season,” said Mark Burdett, MLL Chief Revenue Officer.

“The health and safety of our players, coaches, and staff is the number one priority for the 2020 Major League Lacrosse Season,” said Mark Burdett, MLL Chief Revenue Officer. “We are very thankful and proud to be able to partner with Bidoesix in order to provide efficient and accurate COVID-19 testing for our season.”

Biodesix offers an end-to-end customized solution for COVID-19 detection, including two highly-accurate diagnostic tests: the SARS-CoV-2 ddPCR Test (molecular) and the Platelia SARS-CoV-2 Total Ab Test (antibody). The molecular test diagnoses active COVID-19 infection with a high degree of accuracy. The antibody test identifies patients who may have previously been infected by COVID-19 and may have developed some level of immunity against the virus. Results for both tests are available approximately 24 hours after the sample is received at the Biodesix Laboratory.

“Major League Lacrosse has found an innovative solution to the challenge that COVID-19 presents to professional sports, and Biodesix is proud to be a part of that solution and eager to help implement it,” said Scott Hutton, CEO of Biodesix. “Our expertise, diagnostic technologies, and laboratory qualifications have equipped us to offer nationwide support to combat the COVID-19 pandemic, and we are thrilled at the opportunity to use our capabilities to help MLL operate its 2020 season safely.”

MLL, under the guidance of a team of medical professionals from all six MLL markets, has developed a comprehensive strategy to ensure the health and safety of players, staff, and all personnel on site for the 2020 season. MLL has established a COVID Safety Protocol Officer to oversee the adherence and execution of the safety plan. Major League Lacrosse’s 20th Anniversary Season will be held from July 18-26 at the Navy-Marine Corps Memorial Stadium in Annapolis, Maryland and games will air on ESPN2 and ESPN+.

About Major League Lacrosse
Major League Lacrosse (MLL), based in Boston, is the premier professional outdoor lacrosse league. MLL has led lacrosse’s growth into the mainstream of competitive team sports since 2001. In the spring of 2018, MLL entered into new leadership for the first time in 17 years when it selected Alexander Brown as the Commissioner. Since that time, MLL has been on an aggressive path towards sustainably developing and growing the league. In 2019 MLL welcomed ten new partners to the league, introduced a creative and sophisticated digital team (generating 194% growth in social traffic, 122% growth in social engagement and 393% growth in web traffic) and achieved a 16% increase in total attendance year-over-year. The 2020 season will be Major League Lacrosse’s 20th Anniversary Season. 

Additional League Information
Website: majorleaguelacrosse.com
Instagram: @majorleaguelax
Twitter: @MLL_Lacrosse

About Biodesix
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy consisting of the Nodify XL2™ test and the Nodify CDT™ test evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit


Jordona Jackson Smith for Biodesix
(805) 674-7347

Topics: In the News